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Abstract
Aptamers are small and specific oligonucleotides [RNA or single-strand DNA 
(ssDNA)] with a high binding affinity against target protein. In vitro selection process 
of aptamer by selective evolution of ligands by exponential enrichment (SELEX) has 
been invented in 1990 by Larry Gold and Jack Szostak. SELEX is a random amplification 
of target protein with combined oligonucleotide libraries and selection of synthesized 
aptamer by magnetic beads, affinity chromatography, and capillary electrophoresis-
based methods. According to their low molecular weight, non-immunogenic feature 
in vivo, low production cost, high thermal stability, increase in production potential, 
and ample of modification capacities, aptamers are becoming essential medical tools 
for diagnosis and treatment of diseases such as macular degeneration, hemophilia, 
heart disease, and various cancer types. The therapeutic potential of aptamers, with 
high binding affinity against carcinogenesis-associated growth factors, receptors, or 
proteins frequently overexpressed in specific cancers such as prostate, breast, colon, 
lung, leukemia, hepatocellular, and cervical carcinoma. The strategies for aptamer-
based drugs in cancer therapy design/modify aptamers against cancer biomarkers, 
accelerate immunotherapy targeting immune system, and increase the drug delivery 
in cancer cells. In conclusion, aptamers are promising candidate drugs due to their 
antiproliferative effect on cancer cells and the drug delivery systems during cancer 
chemotherapy.
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1. Introduction
Aptamer is derived from one Latin and one Greek word combinations: “aptus,” which 
means “fit,” and “meros” meaning “particle” [1]. As a DNA or RNA oligonucleotide, aptamer 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
has low molecular weight (5–40 kDa) and three-dimensional (3D) structure with a high 
binding affinity against target protein. Synthesis of aptamers by selective evolution of 
ligands by exponential enrichment (SELEX) has been invented in 1990 by Larry Gold and 
Jack Szostak and the other laboratories concomitantly [2]. SELEX is a consecutive processes 
starting with binding of target with random sequence of oligonucleotide library, wash-
ing and elution of unbound oligonucleotides, amplification of 3D structure oligonucle-
otides against the target epitope via polymerase chain reaction (PCR), selection of aptamers 
with high binding affinity and specificity, and finally modifications of novel aptamers to 
increase stability and function [3]. Through SELEX, an aptamer against various targets 
can be synthesized such as amino acids, peptides, protein, phospholipids, carbohydrates, 
nucleic acids, antibiotics, metal ions, and whole cell (bacteria, viruses). Although aptamers 
are similar to antibodies due to their binding affinity to target molecule, they have a num-
ber of advantages such as small and low complexity with low immunogenic activity, high 
stability, high affinity and specificity for their targets, and easy to synthesize and modify 
in vitro [4].
1.1. SELEX method
The determination of oligonucleotides from a random ssDNA/RNA sequence pool is 
accomplished through in vitro selection referred as SELEX. SELEX method is composed 
of following various steps: (i) design and synthesis of oligonucleotide library (DNA or 
RNA), (ii) hybridization of target with oligonucleotide library, (iii) elimination of aptam-
ers unbounded to target, (iv) selection of aptamers that are highly specific against target 
(4–20 rounds), (v) amplification of selected aptamers by PCR (ssDNA library) or RT-PCR 
(RNA library) in order to increase aptamer efficacy, (vi) cloning of selected and ampli-
fied  aptamers in vector (TOPO cloning vector), (vii) sequence determination of cloned 
 aptamers, and (viii) discriminate and identify the novel aptamer from aptamer database 
tools [5].
Oligonucleotide libraries are the major nucleic acid-based tool to generate aptamer via using 
SELEX method. Classical SELEX libraries are generally 1014–1016 molecules with 20–80 nucleo-
tides long and usually amount of 10−8–10−10 M. They are arranged in order of sequences with 
three parts: 5′ sense primer sequence, random nucleotide, and 3′ antisense primer sequence 
parts, respectively. 5′- sense or 3′-antisense sequence part of the oligonucleotide libraries are 
18–22 base long, and the random sequence between 5′ and 3′ sequences ranges from 20 to 40 
nucleotides (Figure 1) [6].
Besides classical libraries, different featured libraries can be used for SELEX method such 
as structurally modified, based on a known sequence, free of fixed sequences or genomic 
sequences. In structurally modified libraries, between two fixed sequences, a random region 
constructed to form a secondary structure (G-quartets, hairpin, vs) in order to select more 
stable aptamer against target molecule [7]. A library used for SELEX is constructed with 4–6 
nucleotide-fixed regions in both sides called a free of fixed sequence oligonucleotide library 
(tailored SELEX) [8].
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In addition, to investigate for sequences such as transcription factors, translation regulators, 
and splicing sequences, genomic sequence-based libraries are used for genomic SELEX. In 
genomic SELEX, the oligonucleotide libraries are composed of 50–500 nucleotides long with 
fixed sequences on each region [9]. In order to protect aptamers from nucleases, chemical 
modifications such as L-form of nucleotides (L-ribose or L-deoxyribose); 5-iodo-, 4-thiouri-
dine, 5-bromo oligonucleotides; or 5′ fluorescein isothiocyanate (FITC) dye and/or 3′- biotin 
labeling can be performed [10].
Since SELEX method is composed of generation of aptamer against target molecule by using 
a rich random nucleotide sequence of oligonucleotide libraries, there are modifications on 
SELEX method according to research aim such as nitrocellulose membrane filtration-based 
SELEX, affinity chromatography and magnetic bead-based SELEX, capillary electrophore-
sis-based SELEX, microfluidic-based SELEX, cell SELEX, and others [electromobility shift 
assay (EMSA), surface plasmon resonance (SPR)]. In nitrocellulose membrane filtration-
based SELEX, following at least 12 SELEX selection rounds, aptamers are separated via 
the nitrocellulose membrane [11]. The strategy of affinity chromatography-based SELEX 
method is depending on the selection of aptamers generated against target protein that is 
tagged with glutathione-S-transferase (GST) or His-tag and immobilized on beads such as 
agarose [12]. By using affinity column containing target-immobilized beads to select the 
Figure 1. Schematic representation of SELEX method.
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SELEX-generated aptamers, however, the disadvantages of this technique because of untagged 
proteins or protein functional group unbeaded could not be accomplished. However, with-
out  bounding process for target protein, successful and specific aptamers can be selected 
by using magnetic bead technology [13]. In capillary electrophoresis-based SELEX, aptamer 
can be selected by electromobility difference of target, library, and target-library complex 
mixture under electroosmotic flow within few rounds such as 2–4. Theoretically, separation 
potential of aptamers depends on the speed, sample dilution, resolution, and ionic charge of 
each analyte under the influence of electric field within the capillary [14]. In order to decline 
the SELEX rounds, microfluidic-based SELEX is generated to increase the effective capacity 
of aptamer selection under the influence of microfluidic system principle on microchips. 
The most essential advantage of this method is rapid and automatically aptamer selection 
procedure [15]. Although SELEX is generally used for selection of aptamer against proteins, 
a whole cell can also be used as a target for SELEX method. In cell SELEX, extracellular 
proteins expressing on cell surface are generally regarded as a target for cell SELEX and, 
following round of SELEX method with whole cell and the oligonucleotide library, genera-
tion of aptamers against surface proteins on target cells. As the target cell expressing various 
extracellular receptors, ligands, etc. on cell surface, the aptamer selected from cell SELEX can 
be a mixture of aptamers targeting different surface proteins. However, aptamers generated 
by cell SELEX can be used for cell-specific diagnosis and therapy, targeting cell drug delivery 
(Figure 2) [16].
The investigation of potential chemotherapeutic effect of selected aptamers generated by 
SELEX is identified for their novelty in various bioinformatics tools given below [17]:
http://www.cas.org/SCIFINDER/scicover2.html
https://www.hsls.pitt.edu/obrc/index.php?page=URL1096043955
http://connection.ebscohost.com/c/articles/45243053/aptamer-database
By these different and multifunctional SELEX methods, a number of aptamers can be gener-
ated and selected. Subsequently, these aptamers can be used for aptamer-based sensors, new 
drugs, and drug delivery systems. Until now, various aptamers against target proteins are gen-
erated and investigated for preclinical studies, and some are under clinical trials such as Phases 
I and II (Table 1) [18]. Macugen (EYE001), FDA-approved modified RNA aptamer, phase II/III 
completed for the treatment of age-related macular degeneration (AMD). This RNA aptamer 
is referred as Pegaptanib (Pfizer, NY, USA), and it targets vascular endothelial growth fac-
tor (VEGF) [19]. Zimura (ARC1905) is an anti-C5 aptamer that targets essential inflammatory 
mediator, complement component. Phase I study of zimura and monoclonal antibody frag-
ment for angiogenesis factor VEGF combination treatment was completed in AMD patients 
[20]. Another RNA aptamer against factor IXa is REG1 that acts as an anticoagulation system, 
and phase I and phase II trials are successfully accomplished to prevent thrombotic and isch-
emic complications [21]. Fovista is referred to as E10030, an aptamer against platelet-derived 
growth factor (PDGF). The phase I and phase II studies of fovista in neovascular AMD have 
been accomplished. In addition, fovista with anti-VEGF therapy combined treatment is tried in 
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recruited participants [22]. AS1411 is a 26-nucleotide-long guanine-rich oligodeoxynucleotide 
aptamer that targets nucleolin-1, a phosphoprotein expression on various cancer cell surfaces. 
Phase II trials of AS1411 in treatment of myeloid leukemia and metastatic renal cell carcinoma 
have been accomplished. In addition, the treatment potential of AS1411 is inclined by combi-
nation of aptamer with chemotherapeutic drugs such as doxorubicin [23]. The AR19499 is a 
DNA aptamer with high binding affinity against tissue factors Xa and VIIa and leads to tissue 
factor pathway inhibition. Thus, AR19499 DNA aptamer is used in hemophilia which is a 
blood clotting deficiency due to improper clotting factor activity [24].
Figure 2. Steps of cell SELEX.
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2. Aptamer-based drugs for cancer therapy
Drugs for the cancer treatment are generally focused on the inhibition of molecular signal-
ing pathways, cell cycle inhibition, and induction of apoptosis. Chemotherapy is one of the 
major categories for the treatment of cancer; however, its success remains limited due to the 
ineffective accessibility of drugs to tumor cells. Furthermore, high doses of drugs are used 
to overcome this handicap causing intolerable toxicity and multidrug resistance. Drug resis-
tance is the major obstacle in cancer therapy; thus the development of new technologies and 
agents needs to be investigated to overcome drug resistance and prevention of cancer invasion, 
or metastasis [25]. Because of their high binding affinity and specificity, aptamers become an 
essential target for cancer drug development. Aptamer-based drug design depends on target-
ing the cancer-specific biomarker proteins and increases the immunomodulatory functions by 
aptamers, using aptamers as a drug delivery system in cancer treatment [26].
2.1. Cell-specific targets for aptamer-based therapeutic strategies
New strategies for cancer treatment have been developed on the microarray analysis of cancer tis-
sue samples compared to normal tissue’s expression profiles. According to microarray analysis, 
the significant upregulation of specific genes compared to normal tissue samples is shown with 
their biomarker potential. Therefore, the development of stable and selective inhibitors for these 
targets has been analyzed for cancer therapy [27]. One of the essential potential inhibitor for these 
target molecules are aptamers that are more sensitive and specific to their target via high affinity. 
Thus, aptamer-based drugs are designed and synthesized by SELEX method to investigate first 
for their binding affinity and potential chemotherapeutic potential in specific cancer types.
2.1.1. Pegaptanib
One of the essential molecules for induction of angiogenesis and to increase vascular per-
meability is vascular endothelial growth factor (VEGF). The isoforms of VEGF are 206, 189, 
Aptamer Target Disease Trial number Phase References
Zimura Complement 5 (C5) Idiopathic polypoidal 
choroidal vasculopathy
NCT02397954 II [20]
EYE001 VEGF Neovascular age-related 
macular degeneration
NCT00021736 II/III [19]
E10030 PDGF Neovascular age-related 
macular degeneration
NCT00569140 I [22]
REG1 Coagulation factor IXa Coronary and heart 
disease
NCT00113997 I [21]
AS1411 Nucleolin Acute myeloid leukemia NCT01034410 II [23]
AR19499 Tissue factor pathway 
inhibitor (TFPI)
Hemophilia NCT01191372 I [24]
Table 1. Aptamers in the treatment of different diseases.
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165, 145, or 121 amino acids long; one of these isoform VEGF165 overexpression in ovarian 
cancer cells has been demonstrated. In xenograft mice models, inclined levels of VEGF165 
triggered ovarian cancer metastasis, and macrophage infiltration is also determined [28]. The 
successful designed aptamers against VEGF also put forward a clinical potential in the treat-
ment of metastatic tumors [29]. 0.75–1.4 nm Pegaptanib, RNA aptamer against VEGF-165, 
inhibited VEGF-associated tumor vascularity, VEGF signaling via blocking phosphoryla-
tion of VEGFR2 receptor and phospholipase Cγ, and calcium mobilization [30]. Similar to 
Pegaptanib, SL(2)-B/RNV66, DNA aptamer is used to inhibit VEGF-mediated tumor neovas-
cularization in hepatic and breast cancer cells [31].
2.1.2. A9g RNA aptamer
Prostate-specific membrane antigen (PSMA), as a prostate cancer marker when overexpressed, 
is a type II membrane-associated metallopeptidase. Many other solid tumors exhibited PSMA 
expression in their vasculature. Elevated expression of PSMA on the surface of prostate can-
cer cell membrane leads scientific focus on PSMA antigen to synthesize aptamer against it. 
A9g PSMA aptamer is used to target PSMA, which is poorly expressed in normal cells, and 
it is a transmembrane glycosylated protein (100 kDa), which exerts NAALADase/glutamate 
carboxypeptidase II activity on surface of the cells [32]. According to previous reports, block 
PSMA activity was obtained following A9g aptamer, a 2′-F modified RNA treatment. This 
modification increased the aptamer stability in serum. Although two different modifications 
were done during the experiments as 2′ F and 2′ O-Me adducts, 2′ O-Methylation did not 
increase stability. Treating animals with A9g by systemic administration prevented metastatic 
potential of prostate cells. The therapeutic efficiency of aptamer was high because only 10% 
mice models showed bone metastasis. When authors checked the safety of aptamer, animals 
did not exert any change for their weight, blood chemistry, or behavior within 4 weeks [33].
2.1.3. HPV16 E6 (F5) aptamer
Human papillomaviruses (HPVs) are DNA tumor viruses that infect epithelial cells, and they 
are known widely as causality factors of cervical, head, and neck cancers. Although there are 
more than 100 different types of HPV strains identified, one of the most common malignancy- 
associated HPV stain (HPV 16) causes the transformation of viral oncoprotein E6 and E7 in the 
cervical cells, which leads to inhibition of key tumor suppressors [34]. Postsynaptic density 
protein (PDZ) domain is discovered as Drosophila disk large tumor suppressor and is found 
in E6 targeting proteins (e.g., Magi, Dlg), which maintains interaction via short C-terminal 
PDZ-domain-binding motif (ETQV). The designed and selected RNA aptamer (F2) against 
HPV16 E6 was tested in cervical carcinoma cells, which express HPV16 E6 and E7 leading 
to induction of apoptosis through inhibiting interaction between E6 and the PDZ1 domains 
from Magi-1 in p53-independent manner [35].
2.1.4. ErbB targeting aptamers
The EGFR/ErbB family of receptor tyrosine kinases (RTK) comprises four members—
EGFR (also known as HER1 or ErbB1), ErbB2 (Neu, HER2), ErbB3 (HER3), and ErbB4 
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(HER4)—containing an extracellular ligand binding region, a single membrane-spanning 
region, and an intracellular tyrosine kinase-containing domain [36]. Amplification and over-
expression of ErbB2 have been also reported in numerous cancers, including breast, ovarian, 
stomach, bladder, salivary, and lung cancers. One of the promising RNA aptamers is devel-
oped against ErbB2, which overexpressed in majority of breast cancer cells. The designed 
RNA aptamer showed high affinity and specificity against extracellular domain of ErbB2 
protein [37]. EGFR is a critical target, and FDA-approved two monoclonal antibodies (cetux-
imab, panitumumab) and three tyrosine kinase inhibitors (erlotinib, gefitinib, and lapatinib) 
are effective in the treatment of lung cancer patients [38]. However, the presence of increasing 
refractory cases is the major obstacle in the treatment of lung cancer. Thereby, more potent or 
synergizing therapeutically options gain researcher’s interest in cancer field. One of suggested 
therapeutic tools is CL4, a nuclease-resistant RNA aptamer. It is able to bind at high affinity 
to EGFR (ErbB1, Her1) on the surface of different cancer cells and to block EGFR downstream 
signaling via dimerization of receptors. The apoptotic effect of CL4 was shown in in vitro and 
in vivo experimental models. One of the other promising EGFR targeting RNA aptamers is 
E0727/CL428/KD11 30/TuTu2231, which blocks EGFR phosphorylation and EGFR-mediated 
PI3K/AKT and MAPK signaling, which led to increased apoptotic ratio in glioblastoma [39] 
and breast [40] and squamous cell carcinoma [41].
2.1.5. A30 aptamer
One of the members of receptor tyrosine kinase family member type I is human epidermal 
growth factor receptor-3 (HER3), and upregulation of HER3 expression has been dem-
onstrated in various cancer types. Although the expression of HER3 is not high when 
compared to HER2 in cancer tissue samples and/or cancer cell lines, increase HER3 levels 
are evaluated to accelerate the drug resistance. RNA aptamers are selected for the extra-
cellular domain of HER3 (82 kDa domain) by SELEX. One of the RNA aptamers with 
high binding affinity against HER3ECD is A30 aptamer, which has an inhibitive effect on 
heregulin-mediated HER2 phosphorylation and MAPK signaling in MCF-7 breast cancer 
cells [42].
2.1.6. OPN aptamer
Osteopontin (OPN) is a secreted phosphoprotein that induced tumorigenesis, local growth, 
and metastasis in a variety of cancers. It is a potential therapeutic target for the regulation of 
cancer metastasis. OPN is also referred to as cell attachment protein and cytokine that signals 
through two cell adhesion molecules: αvβ3-integrin and CD44 [43]. The selected RNA aptamer 
against OPN was effective to block cell migration and invasion in metastatic MDA-MB-231 
breast cancer cells. The similar findings were confirmed in vivo through xenograft model of 
MDA-MB-231 cell-mediated tumor formation. OPN-R3 with 2′-O-methyl-substituted nucleo-
tides, 5′-cholesterol modification, and 3′-inverted deoxy thymidine modifications were effec-
tive to decrease tumor volume. Therefore it was suggested that small RNA aptamers have 
potential in the treatment of cancers [44].
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2.1.7. NAS-24 aptamer
Vimentin, one of the essential intermediate filamentous protein, play a role during cell adhesions 
play a role during cell adhesion, migration, and apoptotic cellular processes. Overexpression 
of vimentin in various cancer cells such as prostate cancer, malignant melanoma, lung cancer, 
breast cancer, and gastrointestinal tumor is demonstrated [45]. Increased vimentin expression 
is shown to be linked with cancer invasion and low prognosis potential. NAS-24, an 80-nucle-
otide-long DNA aptamer, targeting vimentin molecule has been investigated for its apoptotic 
potential in mouse ascites’ adenocarcinoma cells in vivo [46]. In order to increase the delivery of 
NAS-24, additional arabinogalactan (AG) and NAS-24 aptamer complex has been investigated 
in mice models with exposure of 1.6 μg/kg for 5 days, and treatment significantly triggered 
twofold apoptotic cell death compared to control mice group [47].
2.1.8. YJ-1 aptamer
According to cancer tissue microarray analysis, ample of tumor antigen is demonstrated in 
cancer progression, metastasis, and invasion. Overexpression of one of essential antigens, 
carcinoembryonic antigen (CEA), is associated with cell adhesion, cancer cell migration to 
the liver, and induction of hepatic metastasis of colon cancer cells. Aptamer against CEA is 
YJ1 aptamer, which is investigated for potential anticancer agent in colon cancer cells in mice 
models and revealed inhibition of metastasis of colon cancer to hepatocellular localization. 
However utilization of CEA aptamers is more potent to monitor disease progression [48].
2.1.9. A-P50 aptamer
A-P50 is a 31-nucleotide RNA aptamer against NF-𝜅B molecule with a high binding affinity 
against DNA-binding domain of NF-𝜅B p50. As a transcription factor, NF-𝜅B activates various 
cytokine expressions and takes role in blocking the effect of radiotherapy and chemotherapy in 
cancer cells. Since NF-𝜅B is a major key molecule in carcinogenesis or cancer drug resistance, 
potential therapeutic effect of aptamer against NF-𝜅B has been investigated in hepatocellular 
carcinoma [49]. A-P50 aptamer targeting NF-𝜅B p50 activation inhibition overcomes the doxo-
rubicin-dependent drug resistance in lung cancer in vitro and in vivo mice models. Therapeutic 
effect of A-P50 aptamer is increased by Dox combined drug delivery, and this drug delivery 
system induced apoptotic cell death in A549 and H1299 in non-small cell lung cancer [50].
2.1.10. AP273 AFP aptamer
Hepatic cell proliferation, growth, and differentiation leading to development of hepatocel-
lular carcinoma are associated with alpha fetoprotein (AFP). Active AFP signaling triggered 
oncogenic mRNA production, which results in investigation of the potential anti- carcinogenic 
effect of aptamer against AFP [51]. AP273, a DNA aptamer selected by capillary SELEX method, 
inhibited invasion and migration of HepG2 and SMMC7721 hepatocellular carcinoma cells. 
Microfluidic chips with magnetic bead bound AFP aptamer are constructed to determine and 
measure the circulating cancer cells as a diagnosis [52].
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As we discussed above, there are a number of DNA or RNA aptamers with increased stability 
and function which are promising drug candidates in future cancer therapy models. When we 
checked the patents displaying this potential, aptamers are the important subjects for intellec-
tual property rights. One of pancreatic ductal carcinoma treatment options with aptamers was 
shown with different functions, as synergistic drug with current therapeutic modalities for pan-
creatic cancer, single agent, and labeling of cancer cells. The selectivity of designed and selected 
aptamers for targeted cells, not normal epithelial cells, is one of the most important successful 
parts of aptamer therapy. Studies on severe combined immunodeficiency (SCID) mice models 
increased the potential therapeutic advantage of proposed aptamers for the next-term clinical 
trials. In the treatment of prostate cancer, one of the other promising DNA aptamers is DML-7, 
which binds to DU145 prostate cancer cells with high affinity in temperature-dependent man-
ner. It is well established that the selectivity of DML-7 against metastatic cell lines was high due 
to the lack of interaction affinity to LNCaP or 22Rv1 prostate cancer cells [53].
2.2. Immunomodulatory aptamers in the treatment of different solid tumors
Tumor immunity is one of the important subjects in the current cancer therapy understand-
ing. The approval of the immunomodulatory monoclonal antibodies in the treatment of dif-
ferent cancer types highlighted the role of effector T cells in antitumor immunity [54]. The 
activation of T cells via antigen-presenting cells (APCs) is proceeded due to T-cell receptor-
triggered antigen-specific signals or co-stimulatory (COS) molecules (such as 4-1BB, CD28, 
and OX40). Although a number of attempts were done with antibody-based molecules to 
alter these interactions for COS molecules, the immunogenic properties of antibody-based 
options are found with limited effectiveness [55]. The designed and selected aptamer against 
4-1BB (a COS receptor that is responsible for the activation and expansion of CD8+ T cells) 
was the first agonistic immunomodulatory aptamer. It is an artificial ligand with high simi-
larity to anti-CTLA that initiates COS signals to boost T-cell survival. The aptamers against 
tumor necrosis factor receptor family members, OX40 and CD28, potentiated T-cell-mediated 
tumor immunity in mice models [56]. OX40 RNA aptamer could exert therapeutic potential 
in melanoma patients. Antagonist effect of Del 60 aptamer (against CTL4) on T-cell prolif-
eration has been demonstrated in vitro studies. This RNA aptamer was found effective in 
in vivo tumor growth in melanoma and bladder tumors. In addition, programmed death-1 
(PD-1) and PDL1 axis against DNA aptamer (MP7) was reported to inhibit PD-L1-induced 
apoptosis of tumor-specific T cells and IL-2 secretion [57]. Due to Treg activation following 
PD-1/PDL1 axis, MP7 aptamer may mediate the Tregs in antitumor immunity [58]. In order to 
deregulate the immunological functions of tumor microenvironment, inhibition of IL-10 and 
IL-4Rα-STAT6 signaling with RNA aptamers 5A1 and CL-42 was found effective to decrease 
tumor growth of colorectal and breast cancer cells. Similar to these achievements, DNA-based 
aptamers against IL-6 and VR11 prevented IL-6 or TNF-α receptor activation in myeloma 
cases [59]. In addition, the angiogenesis and invasion inhibition potential of aptamer bind-
ing IL-4Rα are demonstrated in myeloid-derived suppressor cells, and also IL4Rα aptamer 
induced the migration of T lymphocytes in tumor microenvironment in order to decline the 
cancer volume and size [60]. According to Spiegelmer technology, 2′-Fluoro- or 2′-amino 
pyrimidines or 2′-O-methyl nucleotides modified L-RNA aptamer generated that are resistant 
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against  nucleases. One of the Spiegelmer (L-RNA aptamer, Noxxon Pharma, Germany) forms 
of L-RNA aptamer is Nox-E36, which is normally used to inhibit monocyte chemoattractant 
protein-1 (MCP-1) (CCL2). It is suggested to treat glioblastoma multiform patients, which dis-
play high MCP-1 expression profile [61]. Potential inhibition effect of Nox-E36 DNA aptamer 
on MCP-1 molecule revealed the use of Nox-E36 as an immunomodulatory cancer therapy 
agent in different cancer types. Similar to Nox-E36, Nox-A12 is an anti-chemokine suggested 
in the treatment of different malignancies. 45-mer L-RNA and PEG-derived formula of Nox-
A12 is effective on stromal cell-derived factor-1α (SDF-1α). SDF-1α attracts and activates 
immune and nonimmune cells that bind to chemokine receptors CXCR4 and CXCR7. The 
immunological vulnerability potential of cancer cells increased the experimental success of 
L-RNA aptamers in hematological and solid tumors [62].
2.3. Targeted drug delivery in cancer therapy via aptamers
Recently, new targeted drug delivery approaches have been explored such as nanosystems 
and bio-conjugates leading to successful therapy. Targeted drug delivery systems enable drug 
accumulation within a target zone and usually catalyze the interaction between a drug and its 
receptor via four key steps: retain, evade, target, and release. The system selection depends on 
the specific site of the body. New strategies include the use of aptamers with their high affin-
ity and specificity for targets, easy synthesis, modification, and tissue penetration. In addi-
tion, they are even integrated with a number of nanomaterials including gold nanoparticles, 
carbon nanotubes, DNA micelles, and hydrogels. Such specific approaches are expected to 
enhance the effect of chemotherapeutics with greater selectivity. In this section of the chapter, 
a number of aptamers used as effective drug delivery systems were discussed. Aptamer-based 
drugs for cancer therapy were listed in Table 2.
2.3.1. Prostate-specific membrane antigen
Two specific nuclease-stabilized aptamers, xPSM-A9 and xPSM-A10, able to inhibit the enzy-
matic activity of PSMA, were designed by Lupold et al. in LNCaP cells [63]. The study was 
the first of its kind that RNA aptamers were evaluated for prostate cancer. The truncated 
version of xPSM-A10 was highly selective to PSMA, showing strong affinity to LNCaP cells 
(PSMA+), but not PC3 cells (PSMA-) [64]. The high specificity of the aptamer was further 
used for silencing RNA (siRNA) delivery to cells. siRNA-aptamer complex knockdown was 
comparable to the positive control where siRNA-liposomal transfection reagent protocol was 
used [65, 66]. The study showed the decreasing cell proliferation and apoptosis ratios as a 
consequence of silencing polo-like kinase (PLK1) and B-cell lymphoma 2 (Bcl-2) genes via 
PSMA aptamer-siRNA complexes in LNCaP cells [67]. In addition, authors also delivered the 
siRNA-aptamer complex to the LNCaP cell-bearing mice, obtained tumor size and volume 
reduction, whereas no effect was observed in PC3 (PSMA-) cells. More importantly, siRNA-
aptamer delivery overcame the cytotoxicity and immune response problem in vitro and in vivo 
experiments associated with the liposomal agent-mediated delivery. Anti-PSMA aptamer-
conjugated siRNA strategy was also evaluated for other targets such as eukaryotic elonga-
tion factor 2 (EEF2) [68]. Due to the success of anti-PSMA aptamer-siRNA delivery system, 
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Aptamer name Aptamer target Function Cancer References
A30 HER3 Inhibition of HER2 and MAPK 
signaling
HER-3 overexpressing lung cancer, breast cancer, gastric cancer, 
pancreatic cancer
[42]
A9-g PSMA Suppress the enzymatic activity 
of PSMA
In vivo and in vitro blockage of prostate cancer metastasis [32, 33]
AFP-apt Alpha fetoprotein Suppression of AFP-mediated 
cancer progression pathways
In vitro hepatocellular carcinoma growth and proliferation inhibition [51, 52]
A-P50 NF-ΚB NF-𝜅B phosphorylation 
inhibition
Overcoming resistance profile of lung cancer against doxorubicin 
in vitro and in vivo
[49, 50]
AS1411 Nucleolin Nucleolin-dependent NF-ΚB or 
Bcl2 signaling
Acute myelocytic leukemia, lung cancer, renal cancer, breast cancer, 
pancreatic cancer
[23, 84–90]
E0727/CL428/
KD1130/
TuTu2231
Epidermal growth factor 
receptor (EGFR)
EGFR-mediated PI3K/Akt and 
MAPK signaling inhibition
Squamous cell carcinoma, breast cancer, glioblastoma multiform, 
lung cancer
[36–41]
NAS-24 Vimentin Inhibit cell growth and 
proliferation
Apoptotic cell death induction in adenocarcinoma in vitro and in vivo [45–47]
NOX-A12 CXCL12 Suppress the migration and 
angiogenesis triggered by 
CXCL12
Multiple myeloma, chronic lymphocytic leukemia, glioblastoma 
multiform (with radiotherapy)
[62]
NOX-E-36 CXCL12 CXCL12-induced cell migration 
and angiogenesis inhibition
Incline in vivo drug sensitivity in hematological cancer cells, 
chronic lymphocytic leukemia, and multiple myeloma and in vivo 
radiotherapy success in glioblastoma multiform
[62]
OPN-R3 Osteopontin (OPN) Inhibition of OPN binding to 
OPN receptor
In vivo and in vitro blocking of breast cancer cell migration and 
invasion
[43, 44]
Pegaptanib VEGF-165 Inhibition of angiogenesis via 
suppressing the VEGF
Solid cancer extends angiogenic potential therapy [28–31]
YJ-1 Carcinoembryonic 
antigen (CEA)
Blocking the cross-talk between 
CEA and ribonucleoprotein M4
Colorectal cancer invasion-metastasis inhibition in vitro and in vivo 
colorectal cancer
[48]
Table 2. List of aptamer-based drugs for cancer therapy.
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researches have also investigated its potential for drug delivery. The first drug used for this 
purpose was gelonin which is a ribosomal toxin and protein synthesis inhibitor [69]. Studies 
with gelonin suggested that the effective doses are highly toxic due to its low membrane per-
meability. Chu et al. exposed LNCaP cells to anti-PSMA aptamer conjugated with gelonin in 
order to induce cell death [69].
Aptamer direct conjugation with drugs has a major limitation since drug concentration has 
a direct proportion with aptamer size and binding capacity. To enhance the efficacy of the 
drug delivery using aptamers, recent approaches focused on the conjugation of aptamers 
with functional polymers or nanoparticles. Dhar et al. used anti-PSMA aptamer conjugated 
with poly D, L-lactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG) nanoparticles to 
deliver cisplatin to LNCaP prostate cancer cells [70]. The success of the entry of the aptamer-
nanoparticle-drug complex to the cells was confirmed by fluorescence microscopy through 
green fluorescent-labeled encapsulation of the nanoparticles. Finally, authors were able to 
diminish the effective dose of free cisplatin which has a dose-limiting toxicity and acquired 
resistance problems, with the increase of the drug bioavailability. The same approach was 
also tested for docetaxel on mice with LNCaP tumor cell [70]. Results were promising in 
terms of tumor size/volume and survival. xPSM-A10-doxorubicin complex was used for drug 
delivery studies. The results from these studies increased the efficiency of doxorubicin in 
LNCaP prostate cancer cells. The aptamer-doxorubicin complex was further conjugated to a 
fluorescent quantum dot (QD) to provide high targeting potential. The same study revealed 
that PMSA-mediated endocytosis caused the release of doxorubicin [71]. However, aptamer-
QD-doxorubicin complex was as toxic as free doxorubicin. Other anti-PSMA aptamers are the 
polyethylenimine (PEI)- or polyethylene glycol (PEG)-conjugated ones which were co-deliv-
ered with small hairpin RNA (shRNA) against Bcl-x
L
, the anti-apoptotic gene. These combina-
tions were also succeeded to selectively and potently kill LNCaP cells in vitro [72]. Therefore, 
all these studies demonstrated that aptamer-conjugated nanoparticles with chemotherapeutic 
drugs can be a powerful approach for targeted drug delivery with minimal side effects.
2.3.2. Tenascin-C
Tenascin-C (TN-C) as an extracellular matrix (ECM) protein having role in tissue remodeling 
is expressed during embryonic development, tissue repair, and pathological conditions such 
as chronic inflammation and cancer. It is highly expressed in tumor stroma in glioma and 
breast cancer [73]. TN-C affects several signaling molecules, Dickkopf-1 (DKK1) and Wnt, e.g., 
involved in survival, proliferation, invasion, angiogenesis, and metastasis [74]. Researches 
have designed a single-stranded DNA aptamer via SELEX technology to target TN-C in U251 
glioblastoma cells and modified them with a metal chelator MAG2 for an ideal binding affinity 
[75]. While they injected the final radiolabeled MAG2 aptamer to mouse bearing glioblastoma 
and breast cancer xenografts, resulting positron emission tomography (PET) imaging studies 
showed that the aptamer was localized in tumors. Recently, it was shown that the modified 
TN-C aptamer was uptaken by TN-C-positive U87MG glioblastoma and H460 lung cancer cells 
compared to Sc aptamer, the negative control [76]. In addition, the same study also showed that 
the aptamer has a fast clearance from the blood stream and kidneys. Further evaluations were 
obtained in terms of engineering a multimodal nanoparticle-based Simultaneously Multiple 
Applications of Aptamers in Cancer Therapy
http://dx.doi.org/10.5772/intechopen.75603
41
Aptamers and RGD Targeting (SMART) probe that targets TN-C, integrin αvβ3, and nucleolin 
at the same time. The SMART probe had a better affinity and specificity to several tumors 
like glioma, prostate cancer, cervical cancer, and lung cancer cells [77]. The next generation of 
TN-C aptamer was GBI-10 and shown that it can bind several TN-C peptides in vitro [75, 78]. 
The most important part of the fact that GBI-10 can target several binding sites of TN-C is the 
ability to address multiple splice variants at the same time. GBI-10 aptamer was also suggested 
for the diagnosis of tumor during MRI when subjected to gadolinium; a contrast agent helps 
to determine tumor localization, in a liposome capsule [79]. Therefore, TN-C aptamers due to 
target specificity, small size, and rapid tissue penetration has potential clinical advantages and 
is still tested for targeted drug delivery to the ECM of tumors.
2.3.3. Nucleolin
Nucleolin is an abundant nucleolar protein found in eukaryotic organisms including yeast, 
plants, and mammals. It has several structural domains which help the interaction of nucleo-
lin with various proteins and RNAs, playing role in rDNA transcription and maturation, ribo-
some biogenesis, and nucleocytoplasmic transport. Although it was first described in 1973 by 
Orrick et al., its genomic and proteomic organization was clarified by the end of the 1990s [80]. 
It was elucidated that nucleolin is not only a nucleus resident protein but also is expressed at 
the cell surface of dividing cells, especially in tumor cells and angiogenic blood vessels in cor-
relation with cell proliferation [81, 82]. The membrane-associated nucleolin has been shown to 
function as a growth factor receptor [83]. Human gastric cell lines express cell surface nucleo-
lin which functions as receptors for TNF-α-inducing protein (Tipα) of Helicobacter pylori. Tipα 
upon nucleolin binding induced tumor progression via the activation of TNFα and NF-𝜅B in 
human gastric adenocarcinoma cell lines MKN-1 [83]. Nucleolin silencing, by siRNA, resulted 
in the reduction of cell proliferation and migration. Therefore, studies put forward the cell 
surface nucleolin as a potential target for anticancer therapies.
AS1411, the first designed anti-nucleolin aptamer, is a 26-nucleotide-long guanosine-rich 
DNA sequence having antiproliferative activity [84]. It forms a G-quartet-containing struc-
ture which is resistant to nuclease degradation and remarkably stable in serum. AS1411 
treatment caused the inhibition of NF-𝜅B signaling, DNA replication, cell cycle arrest, and 
apoptotic induction. In addition, it was shown that AS1411 can bind Bcl-2 mRNA resulting 
its destabilization and consequent downregulation in breast cancer cells [85]. In vivo preclini-
cal studies demonstrated the antitumor effect of AS1411 in mice bearing tumor xenografts 
with breast and lung cancer cells [86]. AS1411 was also tested in Phase II clinical trials on 
five patients with renal carcinoma and leukemia. The response against the aptamer was very 
promising in one renal cell carcinoma patient with 84% tumor size reduction and 2-year 
tumor-free progression. The patient whole exome sequencing revealed that AS1411 caused 
missense mutation in mammalian target of rapamycin (mTOR) and fibroblast growth factor 
receptor 2 (FGFR2) genes [23].
Besides the direct anticancer strategy using aptamers acting on nucleolin, cargo delivery into 
cancer cells was tested due to the fact that nucleolin shuttles between the cell surface, cyto-
plasm, and nucleus in dividing cells. Before aptamer strategy, F3, a 34-amino acid peptide 
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able to recognize nucleolin on the cell surface of angiogenic cells, has been used to target 
cancer cells [81]. Radio-labeled F3 peptide was used to deliver α-particle resulting tumor vol-
ume reduction in mouse xenograft models [87]. Aptamers are potentially better over peptides 
due to their high serum stability and immune tolerance. Therefore, AS1411 has been used 
for imaging and drug delivery systems in conjunction with nanoparticles. AS1411-human 
serum albumin (HSA) nanoparticles was used as drug carrier, and the uptake of the complex 
is increased compared to only-aptamer condition in MCF-7 breast cancer cells, but not in 
MCF-10A normal breast epithelial cells. This simple complex by modified HSA nanoparticles 
has been used for paclitaxel delivery and suggested as a way to overcome the limitations 
of paclitaxel toxicity [88]. A similar strategy was followed in gastric cancer. Behrooz et al. 
designed a single-stranded AS1411 together with polyamidoamine (PAMAM)-polyethylene 
glycol (PEG) complex. PAMAM-PEG-AS1411 complex dramatically increased the uptake of 
5-FU by MKN45 gastric cancer cells without toxic effects [89]. PEG conjugated to AS1411 
complex was also used to deliver Bcl-xL-specific shRNA and doxorubicin in AGS gastric ade-nocarcinoma which inhibited the cell growth and enhanced tumoricidal effect of doxorubi-
cin [89]. AS1411 aptamer was conjugated to multimodal nanoparticles also (MFR-AS1411). 
MFR-AS1411-injected mouse bearing C6 rat glioma cell line was observed for the nanopar-
ticle uptake. Authors suggested that aptamer-nanoparticle complex is a candidate for cancer 
diagnosis with MR imaging [90]. All these findings concluded that AS1411 is a particularly 
promising agent for targeted delivery approaches.
2.3.4. Mucin-1
Mucin-1 is a glycoprotein modified by O-glycosylation expressed on epithelial cell surfaces. 
Its expression is increased tenfold in malignancies such as breast, lung, and colon cancer [91]. 
Altschuler et al. showed that glycosylated MUC-1 is subjected to clathrin-coated endocytosis as 
well [92]. Since MUC-1 is a membrane protein and overexpressed in cancer cells with relatively 
low expression in normal tissue, it is an attractive tumor marker for targeted therapy. Therefore, 
MUC-1 aptamer, MA3, was developed to selectively deliver anticancer agents to cancer cells 
such as doxorubicin in vitro. Eighty six base DNA aptamer MA3 was applied to MUC1-positive 
A549 lung cancer and MUC1-negative HepG2 hepatocellular carcinoma cells [93]. The study 
showed that MA3-doxorubicin complex selectively delivered doxorubicin to MUC1-positive 
cells with minimal cross reactivity to albumin. Unlike free doxorubicin which enters cells by 
passive diffusion, aptamer-doxorubicin chooses receptor-mediated endocytosis in A549 cells 
[94]. In addition, three more anti-MUC-1 DNA aptamers were selected by Ferreira et al. that 
can selectively bind breast and pancreatic cancer cells [95]. The efficacy of the aptamer was also 
tested on ovarian cancer cells in a quantum dot-MUC-1-doxorubicin (QD-MUC-1-Dox) com-
bination. In vivo imaging studies revealed that QD-MUC-1-Dox conjugate in a lower concen-
tration was highly cytotoxic than free doxorubicin even in multidrug-resistant ovarian cancer 
cells [96]. MUC-1 aptamer was also conjugated to other nanoparticle structures such as meso-
porous silica nanoparticles (MSNs). Confocal microscopy studies showed that MDA-MB-231 
breast cancer cells that overexpress MUC-1 and MDA-MB-231 tumor-bearing Balb/c mice 
showed increased MSN-MUC-1 aptamer, but not the same scenario for non-tumorigenic MCF-
10A breast epithelial cells. The complex was also used for a successful delivery of doxorubicin 
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to MCF-7 cells [97]. Another MUC-1-targeted aptamer L3 was combined with doxorubicin and 
exhibited selective toxicity to MCF-7 breast cancer cells. Most importantly, L3 aptamer was 
able to evade macrophages [98]. All these results indicated that anti-MUC-1 aptamers have 
potential for targeted drug delivery, diagnosis, and staging of cancer.
2.3.5. Protein tyrosine kinase 7
Protein tyrosine kinase 7 (PTK7) is one of the members of receptor tyrosine kinase family, 
also known as colon carcinoma-4 (CCK-4). PTK7 is highly expressed not only in colon but 
in various human malignancies inducing cell proliferation and metastasis. The first DNA 
aptamer targeting PTK7 was developed in 2006 by Shangguan et al. as the consequence of 
a cell SELEX protocol used in cancer biomarker search for acute lymphoblastic leukemia 
[99]. Forty-one-nucleotide-long aptamer called sgc8c was found selectively bound to PTK7. 
Subsequent studies are performed by other research groups with sgc8c internalized into 
PTK7 overexpressing cells [100, 101]. Sgc8c was conjugated with viral capsid protein MS2 
linked to AlexaFluor488 in Jurkat T leukemia cells, and its efficient binding was determined 
by confocal microscopy [102]. Liposomal nanoparticles were also used for PTK7 aptamer 
delivery into CEM-CCRF cells with low molecular weight dextran as a simulation of drug 
delivery [103]. Next, researchers have conjugated sgc8 to various chemotherapeutics such as 
anthracycline for drug delivery experiments. Huang et al. were able to design the aptamer 
suitable for internalization and transportation to endosome in order to drug release in CCRF-
CEM cancer cells [100]. Other anthracyclines were also combined with sgc8 such as daunoru-
bicin which was highly effective to kill PTK7-expressing cancer cells but not PTK7 negative 
cells [104, 105]. More recently Sgc8 was labeled with a radiochemical, F-18 (18F-fluorobenzyl 
azide). Sgc8-F18 showed high affinity to PTK7 expressing HCT 116 colon cancer and U87MG 
glioblastoma cell lines. The aptamer was rapidly cleared from the blood through kidneys. The 
study suggested that this complex may be suitable for aptamer targeting and drug delivery 
tracking in cancer cells [106]. Consequently, PTK7 targeting aptamers were suggested an 
effective strategy for the specific uptake of chemotherapeutic drugs and minimize their toxic 
effects on normal cells.
2.3.6. Epidermal growth factor receptor
Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase which 
belongs to the ErbB family of receptor tyrosine kinases. EGFR is also considered as the pro-
totype for receptor-mediated endocytosis. Upon binding with growth factors of EGF fam-
ily, EGFR dimerization and autophosphorylation occur. Overexpression or mutant receptor 
expression lead a mitogen signals in various cancer types [107]. The inhibition of EGFR by 
monoclonal antibodies or small molecules such as cetuximab or erlotinib, respectively, has 
been shown as an effective strategy in the combat against cancer; however, it is not the case 
for all tumor types. The ability of ligand binding and endocytosis makes EGFR an ideal target 
for aptamer-mediated drug delivery. First experiments performed by Li et al. evaluated the 
EGFR aptamer conjugation with gold nanoparticles targeting human epithelial carcinoma 
cells line, A431 [108]. EGFR-overexpressing A431 cells were able to internalize the aptamer, 
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however MDA-MB-453 cells with low level of EGFR expression. Li et al. also suggested the 
aptamer has high in vivo stability [109]. Although the strategy is promising, currently there is 
only limited information for EGFR aptamer-mediated targeting.
In conclusion, a number of SELEX method-based aptamers have clinical potential to treat dif-
ferent malignancies as single agents or combination with another classical chemotherapeutics. 
In addition, the novel drug delivery methods enhanced the target-specific therapeutic poten-
tial of aptamers. Although early versions of aptamers exerted stability problems, chemical 
modifications increased their physiological availability. However, limited number of clinical 
trials for the treatment of malignancies with specific aptamers is an obstacle for near-future 
clinical modalities based on aptamers. Due to high specificity with increased stability, aptam-
ers are more potent than monoclonal antibody-based drugs with low cost in cancer therapy.
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